Engineering nanomaterials for glioblastoma nanovaccination

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversity of Fribourg-
Autor(es): dc.contributorUniversidade NOVA de Lisboa-
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorTechnion – Israel Institute of Technology-
Autor(es): dc.creatorHameedat, Fatima-
Autor(es): dc.creatorMendes, Bárbara B.-
Autor(es): dc.creatorConniot, João-
Autor(es): dc.creatorDi Filippo, Leonardo D.-
Autor(es): dc.creatorChorilli, Marlus-
Autor(es): dc.creatorSchroeder, Avi-
Autor(es): dc.creatorConde, João-
Autor(es): dc.creatorSousa, Flávia-
Data de aceite: dc.date.accessioned2025-08-21T21:51:29Z-
Data de disponibilização: dc.date.available2025-08-21T21:51:29Z-
Data de envio: dc.date.issued2025-04-29-
Data de envio: dc.date.issued2024-09-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1038/s41578-024-00684-z-
Fonte completa do material: dc.identifierhttps://hdl.handle.net/11449/301782-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/301782-
Descrição: dc.descriptionGlioblastoma is a lethal brain cancer with treatment resistance stemming from its interactions with the surrounding microenvironment and obstacles such as the blood–brain barrier. Conventional therapies such as surgery and chemotherapy have shown limited efficacy, whereas immunotherapies, effective in other solid cancers, face obstacles in glioblastoma owing to its unique immunological dysfunction. Despite the development of peptide, neoantigen, cell-based and mRNA-based vaccines, progress to advanced clinical trials has been sluggish. Factors contributing to this slow progress include the immunosuppressive microenvironment of the tumour, the presence of the blood–brain barrier and the inherent instability of glioblastoma vaccines, collectively hindering treatment efficacy. In this context, nanomaterials have emerged as promising owing to their capacity to cross the blood–brain barrier, shield therapeutics from degradation and efficiently target the brain. In this Perspective, we highlight the development of glioblastoma nanovaccination, discussing strategies for nanoparticle engineering to breach the blood–brain barrier and target both immune and glioblastoma cells, paving the way for potential breakthroughs in glioblastoma treatment.-
Descrição: dc.descriptionAdolphe Merkle Institute University of Fribourg-
Descrição: dc.descriptionChemistry Department University of Fribourg-
Descrição: dc.descriptionToxOmics NOVA Medical School Faculdade de Ciências Médicas NMS|FCM Universidade NOVA de Lisboa-
Descrição: dc.descriptionSchool of Pharmaceutical Sciences São Paulo State University (UNESP)-
Descrição: dc.descriptionDepartment of Chemical Engineering Technion – Israel Institute of Technology-
Descrição: dc.descriptionNational Center of Competence in Research Bio-Inspired Materials University of Fribourg-
Descrição: dc.descriptionSchool of Pharmaceutical Sciences São Paulo State University (UNESP)-
Formato: dc.format628-642-
Idioma: dc.languageen-
Relação: dc.relationNature Reviews Materials-
???dc.source???: dc.sourceScopus-
Título: dc.titleEngineering nanomaterials for glioblastoma nanovaccination-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.